23:28 , Nov 2, 2018 |  BioCentury  |  Finance

Bye-bye, build-to-buy

As another Inception Sciences Inc. company secures an exit, Versant Ventures plans to move away from its build-to-buy model to focus on creating stand-alone companies with broader portfolios and investor syndicates. On Oct. 31, Ophthotech...
20:56 , Aug 17, 2017 |  BC Innovations  |  Finance

Built to purpose

With almost 40 start-ups engaging in build-to-buy deals since 2013 and an average 2-4 years for up or down decisions, the next year could see a spate of acquisitions -- or options declined -- that...
19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
00:38 , Apr 28, 2017 |  BC Innovations  |  Finance

Hatching VC incubators

While more VCs have created venture incubators to nurture early concepts into full-fledged start-ups, they are aligned more on the need to incubate than on how best to do it. Indeed, a collection of VCs...
08:00 , Dec 15, 2014 |  BioCentury  |  Finance

Versant's voyage

Many life science VCs have narrow geographic footprints, but Versant Ventures has instead expanded operations to Canada and Europe, where it believes there are both good research, and untapped opportunities. The firm also is forgoing...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Company News

Versant, Roche, Inception Sciences deal

Roche partnered with Versant and drug discovery company Inception Sciences to launch newco Inception 5 to screen and develop small molecules for myelin repair in multiple sclerosis (MS). Inception 5 has rights to a remyelination...
07:00 , Jun 30, 2014 |  BioCentury  |  Emerging Company Profile

Inception 5: Myelin layer

Inception 5 Inc. is among a handful of companies pursuing the next frontier of multiple sclerosis treatments - compounds that induce remyelination. The company is using a screening platform to discover small molecules that could...
01:02 , Jun 24, 2014 |  BC Extra  |  Top Story

Roche, Versant, Inception launch remyelination newco

Roche (SIX:ROG; OTCQX:RHHBY) partnered with Versant Ventures and drug discovery company Inception Sciences Inc. (San Diego, Calif.) to launch newco Inception 5 to screen and develop small molecules for myelin repair in multiple sclerosis (MS)....
08:00 , Nov 25, 2013 |  BC Week In Review  |  Company News

Inception 4 Inc., Inception Sciences, Bayer ophthalmic news

Bayer's Bayer HealthCare AG unit, Versant Ventures and drug discovery company Inception Sciences launched Inception 4 to conduct early research to develop treatments for ophthalmic disorders. Versant will provide equity financing, and Bayer will provide...
08:00 , Jan 17, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Other

Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Hearing loss g-Secretase; notch 1 (NOTCH1) Studies in cell culture and in rodents suggest blocking NOTCH1 processing using g-secretase inhibitors could help treat hearing loss....